{"id":51756,"date":"2022-12-08T21:02:09","date_gmt":"2022-12-08T20:02:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/"},"modified":"2022-12-08T21:02:09","modified_gmt":"2022-12-08T20:02:09","slug":"midocean-partners-exits-nutrabolt-investment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/","title":{"rendered":"MidOcean Partners Exits Nutrabolt Investment"},"content":{"rendered":"
\n

\nNutrabolt Experienced Transformational Growth During MidOcean\u2019s Ownership<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–MidOcean Partners (\u201cMidOcean\u201d), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced its successful private equity investment exit from Nutrabolt, a rapidly growing, global active health and wellness company with a portfolio of market leading performance-oriented brands, including C4\u00ae Energy, one of the fastest-growing performance energy drink brands in the U.S. In conjunction with MidOcean\u2019s exit, Keurig Dr Pepper (NASDAQ: KDP), a leading North American beverage company, will enter into a strategic partnership with Nutrabolt including a long-term sales and distribution arrangement and an equity investment.\n<\/p>\n

<\/a><\/p>\n

\nSince MidOcean\u2019s investment in Nutrabolt in July 2014, the company has experienced transformational business growth, as evidenced by its significant product and international expansion, building of a global beverage distribution network, development of an e-commerce channel, completion of a strategic acquisition, and receipt of numerous industry accolades. MidOcean\u2019s investment in Nutrabolt is representative of the firm\u2019s track record of partnering with strong branded consumer companies with a differentiated position in the marketplace. To this end, during MidOcean\u2019s ownership, Nutrabolt capitalized on industry-leading trends, which enabled the company to bring differentiated, innovative, well-designed products to the market and cement its status as a leader in the health and wellness category.\n<\/p>\n

\nDaniel Penn, Managing Director at MidOcean, said, \u201cOver the past eight years, Nutrabolt has experienced revenue growth of nearly 4x, enhanced its portfolio of industry leading brands, and clearly defined itself as a top global active health and wellness company. It has been a pleasure working with Doss Cunningham and the entire Nutrabolt team, and we are confident in their ability to continue to grow the company for years to come.\u201d\n<\/p>\n

\n\u201cOur partnership with MidOcean, whose deep industry expertise and experience building successful consumer companies, has been a huge value-add for Nutrabolt as we rolled out significant expansion plans,\u201d said Doss Cunningham, CEO of Nutrabolt. \u201cNutrabolt has grown from a bootstrap startup into one of the fastest growing global active health and wellness companies in the world, and we are extremely excited to execute on our vision for the company\u2019s future.\u201d\n<\/p>\n

\nMidOcean\u2019s investment in and exit from Nutrabolt, build upon the firm\u2019s strong history of successful consumer investments and proven ability to leverage extensive resources, experience, and investment discipline to identify attractive thematic opportunities within targeted sub-sectors. The firm targets stable platforms with multiple growth opportunities, while avoiding cyclical industries. Recent investment highlights include: Casper\u2019s, leading manufacturer and distributor of frozen novelty and other ice cream products; Cloyes, a developer and distributor of mission-critical timing drive systems and components for the auto aftermarket; and FFP, a manufacturer of functional, clean label ingredient solutions for the food and beverage industry.\n<\/p>\n

\nAbout MidOcean Partners<\/b>\n<\/p>\n

\nMidOcean Partners is a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments. Since its inception in 2003, MidOcean Private Equity has targeted investments in high-quality middle-market companies in the consumer and business services sectors. MidOcean Credit Partners was launched in 2009 and currently manages a series of alternative credit strategies, collateralized loan obligations (CLOs), and customized separately managed accounts. For more information, please visit: https:\/\/www.midoceanpartners.com<\/a>.\n<\/p>\n

\nAbout Nutrabolt<\/b>\n<\/p>\n

\nNutrabolt is a fast-growing, global active health and wellness company with a portfolio of market leading performance-oriented brands that energize and fuel active lifestyles. The company’s disruptive and innovative products compete in the Functional Beverage and Active Nutrition segments, under three consumer-loved brands: C4\u00ae (one of the fastest-growing energy drink brands in the United States and the #1 selling global pre-workout brand), XTEND\u00ae (the #1 post-workout recovery brand in the United States), and Cellucor\u00ae (an award-winning sports nutrition brand created in 2002). Since its founding 20 years ago, Nutrabolt has set out to meet the discerning needs of performance athletes and fitness enthusiasts, while appealing beyond this core group to include consumers around the globe who are making healthy, active living a daily priority. Nutrabolt’s portfolio, which is distributed in over 125 countries, is sold through company-owned DTC platforms, Amazon, and other third-party e-commerce marketplaces, and is available at leading retailers across the U.S., including Walmart, Target, 7-Eleven, Walgreens, Kroger, H-E-B, Wawa, Publix, GNC, and the Vitamin Shoppe. For more information about Nutrabolt, please visit www.nutrabolt.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMidOcean Investor Relations:
\n
Allison Donohue
\n
Investorrelations@midoceanpartners.com<\/a>\n<\/p>\n

\nMidOcean Media:
\n
Amanda Shpiner\/Grace Cartwright
\n
Gasthalter & Co.
\n
(212) 257-4170
\n
midocean@gasthalter.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nutrabolt Experienced Transformational Growth During MidOcean\u2019s Ownership NEW YORK–(BUSINESS WIRE)–MidOcean Partners (\u201cMidOcean\u201d), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced its successful private equity investment exit from Nutrabolt, a rapidly growing, global active health and wellness company with a portfolio of market leading performance-oriented brands, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51756","6":"format-standard","7":"category-industry"},"yoast_head":"\nMidOcean Partners Exits Nutrabolt Investment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MidOcean Partners Exits Nutrabolt Investment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Nutrabolt Experienced Transformational Growth During MidOcean\u2019s Ownership NEW YORK–(BUSINESS WIRE)–MidOcean Partners (\u201cMidOcean\u201d), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced its successful private equity investment exit from Nutrabolt, a rapidly growing, global active health and wellness company with a portfolio of market leading performance-oriented brands, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-08T20:02:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MidOcean Partners Exits Nutrabolt Investment\",\"datePublished\":\"2022-12-08T20:02:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/\"},\"wordCount\":745,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005531\\\/en\\\/1659425\\\/21\\\/MidOcean_Profile_Image.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/\",\"name\":\"MidOcean Partners Exits Nutrabolt Investment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005531\\\/en\\\/1659425\\\/21\\\/MidOcean_Profile_Image.jpg\",\"datePublished\":\"2022-12-08T20:02:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005531\\\/en\\\/1659425\\\/21\\\/MidOcean_Profile_Image.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005531\\\/en\\\/1659425\\\/21\\\/MidOcean_Profile_Image.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/midocean-partners-exits-nutrabolt-investment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MidOcean Partners Exits Nutrabolt Investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MidOcean Partners Exits Nutrabolt Investment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/","og_locale":"en_US","og_type":"article","og_title":"MidOcean Partners Exits Nutrabolt Investment - Pharma Trend","og_description":"Nutrabolt Experienced Transformational Growth During MidOcean\u2019s Ownership NEW YORK–(BUSINESS WIRE)–MidOcean Partners (\u201cMidOcean\u201d), a premier New York-based alternative asset manager specializing in middle-market private equity and alternative credit investments, today announced its successful private equity investment exit from Nutrabolt, a rapidly growing, global active health and wellness company with a portfolio of market leading performance-oriented brands, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-08T20:02:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MidOcean Partners Exits Nutrabolt Investment","datePublished":"2022-12-08T20:02:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/"},"wordCount":745,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/","url":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/","name":"MidOcean Partners Exits Nutrabolt Investment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg","datePublished":"2022-12-08T20:02:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221208005531\/en\/1659425\/21\/MidOcean_Profile_Image.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/midocean-partners-exits-nutrabolt-investment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MidOcean Partners Exits Nutrabolt Investment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51756"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51756\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}